Frequency of Class I and II HLA alleles in patients with lung cancer according to chemotherapy response and 5-year survival

KIR2DL2/S2 and HLA-C C1C1 genotype is associated with better response to treatment and prolonged survival of patients with non-small cell lung cancer in a Polish Caucasian population

(2012) Andrzej Wiśniewski et al.   HUMAN IMMUNOLOGY

Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001

(2012) Else-Marit Inderberg-Suso et al.   OncoImmunology

Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer

(2011) Satoshi Hayashi et al.   Journal of Translational Medicine

HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer

(2011) Aifen Lin et al.   LUNG CANCER

Analysis of HLA class I and II alleles regarding to lymph node and distant metastasis in patients with non-small cell lung cancer

(2009) Ismet Bulut et al.   LUNG CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung Cancers

(2008) Hisao Asamura et al.   Journal of Thoracic Oncology

Clinical significance of HLA class I alleles on postoperative prognosis of lung cancer patients in Japan

(2008) Yoshika Nagata et al.   LUNG CANCER